Program
FluBlok
Also written as “UMN-0501”, “Seasonal Influenza Vaccine (SIV) (Flublok)” and “FluBlok®”.
Its studies are mostly in Influenza, Human · Pneumococcal Infections, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Protein Sciences | 30 open or running | phase 3since May 17, 2006 | May 17, 2006 | none ahead |
| Shionogi | 20 open or running | phase 2since Sep 17, 2009 | Sep 17, 2009 | none ahead |
| Sanofi | 10 open or running | phase 3since Oct 3, 2007 | Oct 3, 2007 | none ahead |
| Vaxcyte | 10 open or running | phase 3since Jan 22, 2026 | Jan 22, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2006First study: phase 3 study in Influenza, HumanNew to Protein SciencesProtein Sciences · NCT00328107 · 459 enrolled · United States
- Oct 3, 2007Sanofi's first study: phase 3 study in Influenza, HumanNew to SanofiSanofi · NCT00539981 · 4,648 enrolled · United States
- Oct 4, 2007Phase 3 study in Influenza, HumanProtein Sciences · NCT00539864 · 602 enrolled · United States
- Sep 17, 2009Shionogi's first study: phase 2 study in Influenza, HumanNew to ShionogiShionogi · NCT00980447 · 90 enrolled · Japan
- Sep 2, 2010Phase 2 study in Influenza, HumanShionogi · NCT01195038 · 87 enrolled · Japan
- Mar 11, 2013Phase 3 study in Influenza, HumanProtein Sciences · NCT01825200 · 2,640 enrolled · United States
- Jan 22, 2026Vaxcyte's first study: phase 3 study in Pneumococcal InfectionsNew to VaxcyteVaxcyte · NCT07365826 · 1,390 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07365826Pneumococcal Infections · United States | 3 | Completed | Vaxcyte | Oct 21, 2026 | 1,390 |
| NCT01825200Influenza, Human · United States | 3 | Completed | Protein Sciences | May 2013 | 2,640 |
| NCT01195038Influenza, Human · Japan | 2 | Completed | Shionogi | Jan 2011 | 87 |
| NCT00980447Influenza, Human · Japan | 2 | Completed | Shionogi | Dec 2009 | 90 |
| NCT00539864Influenza, Human · United States | 3 | Completed | Protein Sciences | Apr 2008 | 602 |
| NCT00539981Influenza, Human · United States | 3 | Completed | Sanofi | May 28, 2008 | 4,648 |
| NCT00328107Influenza, Human · United States | 3 | Completed | Protein Sciences | Aug 2005 | 459 |
How it is read
Names in the registry
- “UMN-0501”, 3 entries
- “Seasonal Influenza Vaccine (SIV) (Flublok)”, 1 entry
- “FluBlok®”, 1 entry
- “Flublok”, 1 entry
- “FluBlok Influenza Vaccination”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Pneumococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.